L 6 Hemostasis

advertisement

BLOOD AND BODY DEFENCE

Dr. Amel Eassawi

Dr. Abdelrahman Mustafa

1

HMIM 224

L 6: HEMOSTASIS

2

OBJECTIVES

The student should be able to:

 Define hemostasis and explain the mechanisms that help to achieve it.

 Review the major steps in coagulation.

 Explain how to prevent coagulation.

3

PLATELETS

Formed in bone marrow, 150-400,000 /µl

• The hormone thrombopoietin, produced by the liver stimulate the bone marrow for production of thrombocytes.

• 2-4 µm in diameter, life span 8-12 days, no nucleus

Active Cytoplasm:

 Actin + myosin

 Enzyme synthesis + storage of calcium

 Synthesis of prostaglandins

 Dense granules containing ADP, serotonin and ATP

 Alpha granules (fibrinogen, PDGF (Platelet-derived Growth

Factor), VWF (Von Willbrand Factor), fibronectin)

 Fibrin stabilizing factor

4

PLATELETS

Membrane:

 Receptors: Thrombin, ADP, serotonin.

 Adhesion proteins: VWF, fibronectin, collagen, fibrinogen.

 Coat of glycoproteins: Adhesion to injured areas.

 Phospholipids: Activation of intrinsic pathway

 Adenylate cyclase, cAMP: Activate other platelets

5

HEMOSTASIS

Hemostasis refers to the stoppage of bleeding

• Stages of hemostasis:

• Blood vessel spasm

• Platelet plug formation

• Blood coagulation

6

HEMOSTASIS

1. Blood Vessel Spasm:

• Triggered by pain receptors, platelet release, or serotonin.

• Smooth muscle in blood vessel contracts.

2. Platelet plug formation

• Triggered by exposure of platelets to collagen

• Platelets adhere to rough surface to form a plug

7

HEMOSTASIS

Stages of Platelet Plug Formation:

1. Platelet adhesion

• Von Willebrand factor (VWF)

2. Platelet activation

• Ca ++ releaase

• Granule discharge

• Integrin on surface

• Thromboxane formation (TX

A2

)

3. Platelet aggregation

8

HEMOSTASIS

9

HEMOSTASIS

3.Blood Coagulation:

• Triggered by cellular damage and blood contact with foreign surfaces

• A hemostatic mechanism causes the formation of a blot clot via a series of reactions which activates the next in a cascade.

• Occurs extrinsically (tissue factor pathway) or intrinsically (contact activation pathway).

10

CLOTTING FACTORS

11

CLOTTING CASCADE

• Series of steps involving 12 plasma clotting factors that lead to final conversion of fibrinogen into a stabilized fibrin mesh.

• May be triggered by

 Intrinsic pathway

• Involves seven separate steps

• Factor XII (Hageman factor) is activated by coming into contact with exposed collagen in injured vessel or foreign surface such as glass test tube.

12

Intrinsic Pathway

Figure 36-4;

Guyton & Hall

13

CLOTTING CASCADE

 Extrinsic pathway

• Requires only 4 steps

• Requires contact with tissue factors external to the blood.

• Tissue thromboplastin released from traumatized tissue directly activates factor X.

14

Extrinsic Pathway

Figure 36-3;

Guyton & Hall

15

Clot Pathways

16

17

FATE OF BLOOD CLOTS

• After a blood clot forms it retracts and pulls the edges of a broken blood vessel together while squeezing the fluid from the clot.

• Platelet-derived growth factor stimulates smooth muscle cells and fibroblasts to repair damaged blood vessel walls.

• Plasmin digests the blood clots.

• Plasmin is a plasma protein produced by the liver, present in the plasma as inactive form plasminogen .

• Plasmin is activated in a cascade of reaction involve many factors.

18

PREVENTION OF COAGULATION

• The smooth lining of blood vessels discourages the accumulation of platelets and clotting factors.

• As a clot forms fibrin absorbs thrombin and prevents the clotting reaction from spreading

• Anti-thrombin inactivates additional thrombin by binding to it and blocking its action on fibrinogen.

• Some cells such as basophils and mast cells secrete heparin (an anticoagulant).

19

20

ABNORMAL BLOOD CLOTTING

• Thrombus

– Abnormal intravasculaar clot attached to a vessel wall

• Emboli

– Freely floating clots

• Factors that can cause thromboembolism

– Roughened vessel surfaces associated with atherosclerosis

– Imbalances in the clotting-anti-clotting systems

– Slow-moving blood

– Occasionally triggered by release of tissue thromboplastin into blood from large amounts of traumatized tissue.

• Hemophilia

– Excessive bleeding caused by deficiency of one of the factors in the clotting cascade.

21

COAGULATION DEFECTS

I. Vitamin C Deficiency

- Lack of stable collagen (elderly, alcoholics)

2. Hepatic Failure

- Almost all clotting factors are made in the liver

3. Vitamin K Deficiency

- Required for factor II (prothrombin), VII, IX, and X

4. Hemophilia

22

HEMOPHILIA

• Hemophilia A is classic hemophilia (a disease referring to the inability to clot blood). About 80% is Hemophilia A.

• It is due to deficiency in factor VIII.

• Symptoms include:

– Joint and muscle hemorrhage

– Easy bruising

– Prolonged bleeding from wounds.

• Treatment of hemophilia A is accomplished by infusion of factor VIII concentrates prepared from either human plasma or by recombinant DNA technology.

• Hemophilia B results from deficiencies in IX.

• Hemophilia C results from deficiencies in XI.

23

COAGULATION DEFECTS

• ITP (Idiopathic thrombocytopenic purpura (ITP) is the condition of having an abnormally low platelet count (thrombocytopenia) of unknown cause (idiopathic). autoimmune (common).

• Characterize by bleeding of small capillaries in the skin.

24

ANTIHEMOSTATIC DRUGS

Heparin:

• Activate antithrombin III.

• Antithrombin III inactivates various coagulation factors including thrombin.

• Used in prevention of Deep vein thrombosis (DVT) &

Pulmonary embolism (PE).

• During heart surgery and hemodialysis.

25

ANTIHEMOSTATIC DRUGS

Aspirin:

- An important inhibitor of platelet activation.

- By inhibiting the activity of cyclooxygenase (COX) prostaglandin-endoperoxide synthase (PTGS) ,

- Cyclooxygenase responsible for formation of prostaglandins , prostacyclin and thromboxane .

26

ANTIHEMOSTATIC DRUGS

• The drug clopidogrel: Plavix is an irreversible inhibitor of the ADP receptor on platelet membranes., thus Plavix interferes with the process of platelet aggregation.

• Tissue plasminogen activator (tPA) is highly selective for the degradation of fibrin in a clot. Used particular during the short period following myocardial infarct.

• Streptokinase (an enzyme from the Streptococci bacterium) is another plasminogen activator.

27

TESTS

1. PLATELET DISORDER:

Bleeding Time : The time it takes for the bleeding to stop.

• Normally 2-6 min.

• Increased bleeding time in thrombocytopenia

2. COAGULATION DISORDERS:

1. Clotting Time: The time required for a sample of blood to coagulate in vitro under standard conditions.

• Normally 5-11 min.

• Increased clotting time in hemophilia

2. Partial Thromboplastin Time (PTT)

• For intrinsic & common pathway

• Normally less than 45 sec.

3. Prothrombin Time (PT)

• For extrinsic & common pathway.

• Usually around 12–13 seconds

28

SUMMARY

29

REFERENCES

 Human Physiology, Lauralee Sherwood, seventh edition.

 Text book Physiology by Guyton &Hall,11 th edition.

 Text book of Physiology by Linda S. Contanzo, third edition.

 Physiology by Berne and Levy, sixth edition.

30

Download